Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models

Cancer Research

Volumn 66, Issue 13, 2006, Pages 6732-6740

  Kirpotin, Dmitri B ^a,b   Drummond, Daryl C ^a,b   Shao, Yi ^b   Shalaby, M Refaat ^b   Hong, Keelung ^a,b   Nielsen, Ulrik B ^c   Marks, James D ^c   Benz, Christopher C ^d   Park, John W ^d,e  

^a Hermes Biosciences Inc   (United States)

^b CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; IMMUNOLIPOSOME; LIPID; MACROGOL; MONOCLONAL ANTIBODY; NANOPARTICLE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL; CELL TRANSPORT; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; ENDOCYTOSIS; FEMALE; FLOW CYTOMETRY; GENE OVEREXPRESSION; GENE TARGETING; INTERNALIZATION; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SOLID TUMOR; TUMOR LOCALIZATION; XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; FEMALE; HUMANS; LIPOSOMES; MICE; NANOSTRUCTURES; RECEPTOR, ERBB-2; TRANSPLANTATION, HETEROLOGOUS;

EID: 33746172167     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-4199     Document Type: Article

References (37)

1. Allen TM, Cullis PR. Drug delivery systems: entering the mainstream. Science 2004;303:1818-22.
2. Drummond DC, Meyer O, Hong K, Kirpotin DB, Papahadjopoulos D. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev 1999;51:691-743.
3. Noble CO, Kirpotin DB, Hayes ME, et al. Development of ligand-targeted liposomes for cancer therapy. Expert Opin Ther Targets 2004;8:335-53.
4. Park JW, Hong K, Kirpotin DB, et al. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Clin Cancer Res 2002;8:1172-81.
5. Park JW, Hong K, Carter P, et al. Development of antip185HER2 immunoliposomes for cancer therapy. Proc Natl Acad Sci U S A 1995;92:1327-31.
6. Kirpotin D, Park JW, Hong K, et al. Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro. Biochemistry 1997;36:66-75.
7. Carter P, Rodrigues ML, Park JW, Zapata G. Preparation and uses of Fab' fragments from E. coli. McCafferty J, Hoogenboom HR, Chiswell D, editors. Antibody engineering: a practical approach Oxford, UK: IRL Press; 1996291-308.
8. Poul MA, Becerril B, Nielsen UB, Morisson P, Marks JD. Selection of tumor-specific internalizing human antibodies from phage libraries. J Mol Biol 2000;301:1149-61.
9. Nielsen UB, Kirpotin DB, Pickering EM, et al. Therapeutic efficacy of anti-ErbB2 immunoliposomes targeted by a phage antibody selected for cellular endocytosis. Biochim Biophys Acta 2002;1591:109-18.
10. Nellis DF, Giardina SL, Janini GM, et al. Preclinical manufacture of anti-HER2 liposome-inserting, scFv-PEG-lipid conjugate. 2. Conjugate micelle identity, purity, stability, and potency analysis. Biotechnol Prog 2005;21:221-32.
11. Nellis DF, Ekstrom DL, Kirpotin DB, et al. Preclinical manufacture of an anti-HER2 scFv-PEG-DSPE, liposome-inserting conjugate. 1. Gram-scale production and purification. Biotechnol Prog 2005;21:205-20.
12. 67Gallium-labeled liposomes with prolonged circulation: preparation and potential as nuclear imaging agents. Nucl Med Biol 1993;20:149-55.
13. Hong K, Friend DS, Glabe CG, Papahadjopoulos D. Liposomes containing colloidal gold are a useful probe of liposome-cell interactions. Biochim Biophys Acta 1983;732:320-3.
14. Szoka F, Papahadjopoulos D. Procedure for preparation of liposomes with large internal aqueous space and high capture by reverse-phase evaporation. Proc Natl Acad Sci U S A 1978;75:4194-8.
15. Brunetti A, Blasberg RG, Finn RD, Larson SM. Gallium-transferrin as a macromolecular tracer of vascular permeability. Int J Rad Appl Instrum B 1988;15:665-72.
16. Kirpotin DB, Shao Y, Stauffer P, et al. Local hyperthermia facilitates inmmunoliposome targeting to breast cancer xenografts Proc Am Assoc Cancer Res 2002;43:416.
17. Carter P, Presta L, Gorman C, et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci U S A 1992;89:4285-9.
18. Mamot C, Drummond DC, Noble CO, et al. Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo. Cancer Res 2005;65:11631-8.
19. Otsuki H, Brunetti A, Owens ES, Finn RD, Blasberg RG. Comparison of iron-59, indium-111, and gallium-69 transferrin as a macromolecular tracer of vascular permeability and the transferrin receptor. J Nucl Med 1989;30:1676-85.
20. Papahadjopoulos D, Allen TM, Gabizon A, et al. Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc Natl Acad Sci U S A 1991;88:11460-4.
21. Maruyama K, Takahashi N, Ishida O, Iwatsuru M. Construction of transferrin-PEG-liposomes for intracellular drug delivery in solid tumors in vivo. J Liposome Res 1998;8:81-2.
22. Damert A, Machein M, Breier G, et al. Up-regulation of vascular endothelial growth factor expression in a rat glioma is conferred by two distinct hypoxia-driven mechanisms. Cancer Res 1997;57:3860-4.
23. Takano S, Yoshii Y, Kondo S, et al. Concentration of vascular endothelial growth factor in the serum and tumor tissue of brain tumor patients. Cancer Res 1996;56:2185-90.
24. Huang SK, Lee K-D, Hong K, Friend DS, Papahadjopoulos D. Microscopic localization of Sterically stabilized liposomes in colon carcinoma-bearing mice. Cancer Res 1992;52:5135-43.
25. Yuan F, Lwunig M, Huang SK, Berk DA, Papahadjopoulos D, Jain RK. Microvascular permeability and interstitial penetration of Sterically stabilized (stealth) liposomes in a human tumor xenograft. Cancer Res 1994;54:3352-6.
26. Lewis GD, Figari I, Fendly B, et al. Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies. Cancer Immunol Immunother 1993;37:255-63.
27. r 34,000 is a widely distributed human carcinoma marker. Br J Cancer 1987;56:714-21.
28. Sarup JC, Johnson RM, King KL, et al. Characterization of an anti-p185HER2 monoclonal antibody that stimulates receptor function and inhibits tumor cell growth. Growth Regul 1991;1:72-82.
29. Allen TM, Brandeis E, Hansen CB, Kao GY, Zalipsky S. A new strategy for attachment of antibodies to sterically stabilized liposomes resulting in efficient targeting to cancer cells. Biochim Biophys Acta 1995;1237:99-108.
30. Noguchi Y, Wu J, Duncan R, et al. Early phase tumor accumulation of macromolecules: a great difference in clearance rate between tumor and normal tissues. Jpn J Cancer Res 1998;89:307-14.
31. Huang SK, Mayhew E, Gilani S, Lasic DD, Martin FJ, Papahadjopoulos D. Pharmacokinetics and therapeutics of sterically stabilized liposomes in mice bearing C-26 colon carcinoma. Cancer Res 1992;52:6774-81.
32. Gabizon A, Goren D, Horowitz AT, Tzemach D, Lossos A, Siegal T. Long-circulating liposomes for drug delivery in cancer therapy: a review of biodistribution studies in tumor-bearing animals. Adv Drug Deliv Rev 1997;24:337-44.
33. Northfelt DW, Martin FJ, Working P, et al. Doxorubicin encapsulated in liposomes containing surfacebound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma. J Clin Pharmacol 1996;36:55-63.
34. Park JW, Stagg R, Lewis GD, et al. Anti-p185HER2 monoclonal antibodies: biological properties and potential for immunotherapy. Dickson RB, Lippman ME, editors. Genes, oncogenes, and hormones: advances in cellular and molecular biology of breast cancer Boston: Kluwen 1992. 193-211.
35. Goren D, Horowitz AT, Zalipsky S, Woodle MC, Yarden Y, Gabizon A. Targeting of stealth liposomes to erbB-2 (Her/2) receptor: in vitro and in vivo studies. Br J Cancer 1996;74:1749-56.
36. Lee RJ, Wang S, Turk MJ, Low PS. The effects of pH and intraliposomal buffer strength on the rate of liposome content release and intracellular drug delivery. Biosci Rep 1998;18:69-78.
37. Vail DM, Amantea MA, Colbern GT, Martin FJ, Hilger RA, Working PK. Pegylated liposomal doxorubicin: proof of principle using preclinical animal models and pharmacokinetic studies. Semin Oncol 2004;31:16-35.